Testing immunotherapy plus chemotherapy before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of an immunotherapy drug (tislelizumab) with two chemotherapy drugs (called the SOX regimen) given before surgery for locally advanced stomach cancer. The goal is to see if this treatment can shrink the tumor and make it easier to remove completely during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have stomach cancer or cancer where the stomach meets the esophagus that is locally advanced (has spread into the stomach wall or nearby tissues but not to distant organs).
- You have not had prior chemotherapy or other targeted therapy for this cancer.
- Your tumor tests negative for HER2 and positive for PD-L1 (both are specific markers).
- You are in generally good health (able to care for yourself and do daily activities).
- Your heart, liver, kidney, and blood test results are within acceptable ranges for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding immunotherapy to chemotherapy after surgery for stomach or gastroesophageal junction cancer helps prevent the cancer from coming back. It is for people whose cancer is HER2-negative and who have had the tumor completely removed.
This study compares two treatment plans after surgery for stomach cancer: chemotherapy alone versus chemotherapy plus immunotherapy (a treatment that helps your immune system fight cancer). The goal is to see which plan is better at preventing cancer from returning.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This trial tests whether giving immunotherapy (a treatment that helps your immune system fight cancer) along with chemotherapy and radiation before surgery can help shrink tumors in people with stomach cancer at the esophagus-stomach junction. The goal is to see if this approach is safe and effective before the main surgery.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests whether adding an immunotherapy drug (sintilimab) to two different chemotherapy combinations before surgery can help shrink stomach cancer and improve outcomes. It is for people with locally advanced stomach cancer that can be removed with surgery.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.